| Study Number | Study Phase | Start Date | Recruitment Status |
| 6474IL/0002 | Phase II | 31-May-2002 | Completed |
| An Open-Label, Multicenter Phase II Study to Assess the Response of Subjects With Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy With or Without Capecitabine to ZD6474 (100-Mg or 300-Mg Daily Oral Dose). |
| 6474IL/0003 | Phase II | 15-Apr-2005 | Completed |
| A Phase II, Randomized Double-Blind, 2-Part, Multicenter Study to Compare the Efficacy of ZD6474 with the Efficacy of ZD1839 (Iressa™) in Subjects with Locally Advanced or Metastatic (IIIB/IV) Non-Small Cell Lung Cancer After Failure of First-Line Platinum-Based Chemotherapy and to Assess the Activity of ZD6474 in Subjects Following Failure of Treatment with ZD1839. |
| 6474IL/0004 | Phase II | 23-Oct-2002 | Completed |
| A Phase Two Study of ZD6474 in Patients With Relapsed Multiple Myeloma. |
| 6474IL/0006 | Phase II | 1-Oct-2002 | Completed |
| A Randomized, Double-Blind, Multicenter, Phase II Study to Assess the Safety, Tolerability, and Efficacy of ZD6474 in Combination With Docetaxel (TAXOTERE™) in Subjects with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure of Prior Platinum-Based Chemotherapy. |
| D4200C00008 | Phase II | 15-Nov-2004 | Completed |
| An Open Label, Two Stage, Phase II Study to Evaluate the Efficacy and Tolerability of ZD6474 in Patients with Locally Advanced or Metastatic Hereditary Medullary Thyroid Carcinoma. |
| D4200C00032 | Phase III | 31-Mar-2006 | Active, not recruiting |
| A Phase III, Randomized, Double-Blinded, Multi-Center, Study to Assess the Efficacy of Docetaxel (TAXOTERE™ in Combination With ZD6474 (ZACTIMA™) versus Docetaxel (TAXOTERE™ with Placebo in Subjects With Locally Advanced or Metastatic NSCLC) |
| D4200C00039 | Phase II | 27-Dec-2004 | Completed |
| A Randomised, Double-blind, Parallel-group, Dose Finding Study to assess the Efficacy and Safety of ZD6474 in patients with advanced, metastatic, or recurrent NSCLC who have failed previous chemotherapy regimens, at least one of which contained platinum. |
D4200C00068 | Phase II | 31-Aug-2006 | Completed |
A Phase II, Open-Label Study To Assess The Efficacy and Tolerability of ZD6474 (ZACTIMA™ ) 100 mg Monotherapy In Subjects with Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer. |
| D4200C00044 | Phase III | 9-Nov-2006 | Recruiting |
| A Phase III Study to Assess the Efficacy of ZD6474 (ZACTIMA™) Plus Best Supportive care Versus Best Supportive Care in Patients With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer after Therapy with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI). |
D4200C00057 | Phase III | 23-Aug-2006 | Active, not recruiting |
A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima ™ Versus Tarceva® in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer after failure of at least One Prior Chemotherapy |
| D4200C00058 | Phase II | 1-Dec-2006 | Active, not recruiting |
| An International, Phase II, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study to Assess the Efficacy of ZD6474 (ZACTIMA™ ) versus Placebo in Subjects with Unresectable, Locally Advanced or Metastatic Medullary Thyroid Cancer. |
| D4200C00036 | Phase III | 15-Jan-2007 | Active, not recruiting |
| A Phase III, Randomized, Double-blinded, Parallel Group, Multi-centre Study to Assess the Efficacy and Safety of ZD6474 (ZACTIMA™) in Combination with Pemetrexed (Alimta®) versus Pemetrexed alone in Patients with Locally-Advanced or Metastatic NSCLC. |
| D4200C00062 | Phase I | 28 Dec 2006 | Recruiting |
| Open label, phase I ZD6474 head and neck cancer study (FDMA113 short study title). |
| D4200C00048 | Phase II | 28 Mar 2007 | Completed |
| A phase II, double blind, placebo controlled, randomised study to assess the efficacy and safety of 2 doses of Zactima (ZD6474) in combination with FOLFIRI vs. FOLFIRI alone for the treatment of colorectal cancer in patients who have failed therapy with an oxaliplatin and fluoropyrimidine containing regimen |
| D4200C00007 | Phase II | . | Completed |
| A Randomized, Partially Blinded, Phase II Study to Assess the Safety, Tolerability and Efficacy of ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC). |
| D4200C00046 | Phase II | 20 Jan 2006 | Active, not recruiting |
| A phase II, double-blind, placebo controlled, randomized study to assess the efficacy and safety of ZD6474 in combination with docetaxel (Taxotere™) vs docetaxel alone as 2nd line treatment for advanced breast cancer (ABC). |
| D4200C00050 | Phase I | 6 Sep 2006 | Completed |
| A Phase I, Open-Label Study To Assess The Effect of ZD6474 (ZACTIMA) On Vascular Permeability In Patients with Advanced Colorectal Cancer and Liver Metastases. |
| D4200C00041 | Phase I | 20 Jul 2005 | Active, not recruiting |
| A Phase 1, open-label study to assess the safety and tolerability of ZD6474 in combination with Pemetrexed (Alimta) in patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy. |
| D4200C00054 | Phase I | 23 Aug 2006 | Completed |
| A Phase I, open label study to assess the saftey and tolerability of ZD6474 (ZACTIMA) in combination with Vinorelbine (Navelbine) or Gemcitabine (Gemzar) plus cisplatin as first line therapy in patients with locally advanced or metastatic (Stage IIIB-IV) Non Small Cell Lung Cancer. |
| D4200C00047 | Phase II | 13 Feb 2007 | Active, not recruiting |
| A Phase 2 double-blind, placebo controlled, randomized study to assess the efficacy and safety of 2 doses of Zactime (ZD6474) in combination with FOLFOX vs FOLFOX alone for the treatment of colorectal cancer in patients who have failed therapy with an Irinotecan and fluoropyrimidine regimen. |
| D4200C00055 | Phase II | 14 Dec 2005 | Completed |
| A Phase II double blind placebo controlled randomised study to assess the efficacy and safety of docetaxel (Taxotere)/prednisolone/ZD6474 vs docetaxel/prednisolone/placebo in patients with hormone refractory prostate cancer (HRPC). |
| D4200C00037 | Phase I | 4 Aug 2005 | Active, not recruiting |
| A phase I open label study to assess the safety and tolerability of ZD6474 in combination with 5-Fluorouracil, Leucovorin and Oxaliplatin (mFLOFOX6) as first or second line therapy in patients with advance colorectal adenocarcinoma. |
| D4200C00038 | Phase I | 30 Aug 2005 | Active, not recruiting |
| A Phase I open label study to asses the safety and tolerability of ZD6474 in combination with Irinotecan, 5-Fluorouracil and Leucovorin (FOLFIRI) as first or second line therapy in patients with metastatic colorectal adenocarcinoma. |
| D4200L00004 | Phase I | 26 Sep 2006 | Active, not recruiting |
| An Open-label, phase I rising multiple dose, single-centre study to determine the PK & tolerabilityof ZD6474 at different dose levels in Chinese patients with solid malignancy tumor. |
| D4200C00072 | Phase II | 13 Jul 2007 | Recruiting |
| An Open-label, phase I rising multiple dose, single-centre study to determine the PK & tolerabilityof ZD6474 at different dose levels in Chinese patients with solid malignancy tumor. |
| D4200C00075 | Phase II | 15 Nov 2007 | Recruiting |
| A Randomised Phase II Trial To Evaluate The Efficacy And Safety of VANDETANIB (ZD6474, ZACTIMA™) Versus VINORELBINE in Patients with Inoperable or Relapsed Malignant Mesothelioma. |
| D4200C00079 | Phase II | 17 Oct 2007 | Recruiting |
| A Randomized, Double Blind, placebo-controlled Phase II, Multi-Centre Study to Assess the Efficacy and Safety of Zactima™ in Patients with locally advanced or metastatic papillary or follicular Thyroid Carcinoma failing or unsuitable for Radioiodine therapy. |
| D4200C00080 | Phase II | 4 Feb 2008 | Recruiting |
| A randomized, double-blind phase II trial to assess the efficacy and safety of bicalutamide (Casodex® ) associated to ZD6474 (Zactima™ ) or to placebo in patients with castration-refractory metastatic prostate cancer without any clinical symptom related to disease progression. |
| D4200L00003 | Phase I | 19 Jul 2006 | Recruiting |
| Dose Escalation Study of the Combination of ZD6474, Gemicitabine and Capecitabine in Locally Advanced Unresectable or Metastatic Pancreatic Adenocarcinoma |
| D4200L00010 | Phase II | 14 May 2008 | Recruiting |
| A randomized, double-blind, multicentre, phase II controlled trial assessing ZACTIMATM (vandetanib) against placebo in prolonging the off-treatment interval in prostate cancer subjects undergoing intermittent androgen deprivation hormonal therapy |
|